HARBIN GLORIA PHARMACEUTICALS Co., LTD (SHE:002437)
China flag China · Delayed Price · Currency is CNY
4.730
+0.430 (10.00%)
Aug 20, 2026, 3:04 PM CST

SHE:002437 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
663.65396.4481.96711.281,2381,496
Trading Asset Securities
284.08533.6630-50.56-
Cash & Short-Term Investments
947.73930.06511.96711.281,2881,496
Cash Growth
57.43%81.66%-28.02%-44.79%-13.87%67.04%
Accounts Receivable
138.46128.38128.62207.67236.82235.59
Other Receivables
27.0823.7318.8726.6536.5382.85
Receivables
165.54152.11147.49234.32273.35318.45
Inventory
206.7205.88188.67190.67214.14352.09
Other Current Assets
29.1430.8129.0618.1940.434.17
Total Current Assets
1,3491,319877.191,1541,8162,200
Property, Plant & Equipment
959.27985.511,0291,0591,1191,235
Long-Term Investments
250.1237.51277.56298.23458.25498.33
Goodwill
369.03369.03369.03369.03369.03411.16
Other Intangible Assets
154.5162.98166.66191.3221.18290.34
Long-Term Deferred Tax Assets
15.9616.5316.4621.0133.7724.19
Long-Term Deferred Charges
8.157.9714.458.239.717.21
Other Long-Term Assets
35.4736.274.7351.5846.6218.21
Total Assets
3,1423,1352,8253,1524,0744,695

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
79.2765.1360.4569.8875.48270.49
Accrued Expenses
15.97341.62395.46109.41516.94527.16
Short-Term Debt
20.0290.06-675.691,4551,558
Current Portion of Leases
1.391.381.33---
Current Income Taxes Payable
30.227.7110.239.6710.269.33
Current Unearned Revenue
24.0244.944.250.0383.1786.98
Other Current Liabilities
538.68247.05311.37496.47195.49226.24
Total Current Liabilities
709.56797.85823.031,4112,3362,678
Long-Term Leases
0.140.571.95---
Long-Term Unearned Revenue
12.1112.3212.9217.8721.4324.53
Long-Term Deferred Tax Liabilities
13.0613.1913.2812.1212.8712.55
Other Long-Term Liabilities
1.081.081.081.080.030.82
Total Liabilities
735.96825852.261,4422,3712,716

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
2,2302,2322,2802,1982,1982,198
Additional Paid-In Capital
413.68413.29456.81380.47471.13448.21
Retained Earnings
-209.61-304.54-680.75-913.51-1,034-742.51
Treasury Stock
-40.23-42.93-102.03---
Comprehensive Income & Other
-5.72-4.19-3.09-3.32-4.17-9.61
Total Common Equity
2,3882,2941,9511,6621,6311,894
Minority Interest
17.6415.922.1548.4672.384.7
Shareholders' Equity
2,4062,3101,9731,7101,7041,979
Total Liabilities & Equity
3,1423,1352,8253,1524,0744,695

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
21.5592.013.28675.691,4551,558
Net Cash (Debt)
926.18838.05508.6835.59-166.67-62.42
Net Cash Growth
75.06%64.75%1329.47%---
Net Cash Per Share
0.420.370.220.02-0.08-0.03
Filing Date Shares Outstanding
2,2302,2322,2802,1982,1982,198
Total Common Shares Outstanding
2,2302,2322,2802,1982,1982,198
Working Capital
639.5552154.16-256.7-520.11-477.9
Book Value Per Share
1.071.030.860.760.740.86
Tangible Book Value
1,8641,7621,4151,1011,0411,193
Tangible Book Value Per Share
0.840.790.620.500.470.54
Buildings
-1,2381,2331,2321,2391,310
Machinery
-794.32797.43807.63803.46801.97
Construction In Progress
-1.371.893.0512.891.8